Composition for improving constipation and preparation method thereof

Abstract

The invention discloses a composition for improving constipation and a preparation method thereof, and belongs to the technical field of health food. According to the composition disclosed by the invention, the psyllium seed husks, the xylooligosaccharide and the galactomannan are compounded and matched; compared with similar compositions, the composition disclosed by the invention has a remarkable synergistic constipation improving protection effect. The efficacy of the product is proved through human body trial feeding experiments, and the product is mild and stable in property, does not obviously stimulate gastrointestinal tracts after being used, and can be effectively applied to preparation of medicinal and edible products. The invention further provides a preparation method of the composition, and it is guaranteed that the powder is not huddled and is evenly mixed.

Description

Technical Field

[0001] The invention relates to the technical field of health food, and in particular to a composition for improving constipation function and a preparation method thereof. Background Art

[0002] Constipation refers to an intestinal disease caused by abnormal large intestine conduction function, which is mainly manifested by reduced bowel movements, difficulty in defecation, dry and hard stools, etc., which seriously affects the quality of life. With the change of dietary structure, accelerated pace of life and the influence of social and psychological factors, the prevalence of constipation is on the rise. Epidemiological studies on community populations show that the prevalence of chronic constipation in adults in my country is 4-6%, and increases with age. The prevalence of constipation in people over 60 years old can be as high as 22%. The prevalence of women is higher than that of men, with the ratio of male to female prevalence being 1:1.22-1:4.56.

[0003] At present, the drugs for treating constipation are still mainly chemical drugs. However, chemical drugs are accompanied by certain side effects when treating constipation, and there is a possibility of recurrence of the disease after stopping the drug. Therefore, people are more inclined to use products with dual-purpose raw materials as the main ingredients to improve constipation, reduce gastrointestinal adverse reactions, and relieve symptoms of intestinal discomfort. Summary of the invention

[0004] Based on the defects of the prior art, the purpose of the present invention is to provide a composition for improving constipation. The composition is scientifically screened, and through multi-index and multi-level experimental studies, it is proved that the various components are reasonably matched and synergistic, and have a significant improvement effect on constipation. In order to achieve the above purpose:

[0005] In a first aspect, the present invention provides a composition comprising the following components: psyllium husk, xylo-oligosaccharide, and galactomannan.

[0006] The inventors have found through experiments that the composition prepared by combining these three components has a significant synergistic effect in improving constipation compared with similar compositions. The efficacy of the product can be confirmed by human food trials. The product is mild and stable in nature, does not cause obvious irritation to the gastrointestinal tract after use, and can be effectively used in the preparation of products for both medical and edible purposes.

[0007] In certain embodiments, the galactomannan is hydrolyzed guar gum;

[0008] In certain embodiments, the galactomannan has a molecular weight of 10-50 kDa.

[0009] Guar gum, also known as guar gum, is a natural plant gum extracted from the endosperm of guar beans. The main component of guar gum is galactomannan, which is a water-soluble natural polysaccharide with a molecular weight of up to 5000kDa and a very high viscosity. Hydrolyzed guar gum with different molecular weights and viscosities can be obtained by enzymatic hydrolysis.

[0010] In certain specific embodiments, the psyllium husk, xylo-oligosaccharide and galactomannan are in the form of powder.

[0011] Since the above components are rich in water-soluble active substances, they have higher stability and activity when processed, mixed or stored in a powder state.

[0012] In certain specific embodiments, the mass ratio of psyllium husk, xylo-oligosaccharide and galactomannan in the components of the composition is (10-25): (4-8): (10-20);

[0013] Preferably, among the components of the composition, the mass ratio of psyllium husk, xylo-oligosaccharide and galactomannan is 15:7:15.

[0014] In a second aspect, the present invention provides use of the composition in preparing a product for improving constipation function.

[0015] In certain specific embodiments, the product is a common food or a health food.

[0016] The composition of the present invention has obvious effect on improving constipation function, strong stability, and is easy to process and shape, and is suitable for preparing various types of products, especially ordinary food or health food that can be used as both medicine and food.

[0017] In certain specific embodiments, the components of the health food further include excipients acceptable to health food;

[0018] In certain specific embodiments, the auxiliary material includes at least one of a flavoring agent, a filler, a coating agent, a lubricant, a glidant, and a disintegrant.

[0019] In certain specific embodiments, when the product is a health food, the dosage form of the health food includes tablets, powders, and capsules.

[0020] In a third aspect, the present invention provides a method for preparing the health food described in the second aspect.

[0021] In certain specific embodiments, the health food is a powder, and the preparation method thereof comprises the following steps:

[0022] The psyllium husk, xylooligosaccharide, galactomannan and auxiliary materials are transferred to a mixing device and mixed for 25 to 35 minutes. The materials are discharged and sealed with aluminum foil film. The sealing and stability of the packaging are tested and the materials are put into storage after passing the test. The mass ratio of psyllium husk, xylooligosaccharide and galactomannan is (10 to 25): (4 to 8): (10 to 20).

[0023] Preferably, any one of psyllium husk, xylo-oligosaccharide and galactomannan is pre-mixed with the auxiliary materials, and then the mixture is transferred to a mixing device together with the remaining two components and mixed for 5 minutes.

[0024] More preferably, the auxiliary materials include fillers and glidants.

[0025] More preferably, the filler comprises maltodextrin, resistant dextrin and / or corn starch, and the glidant comprises silicon dioxide and / or tricalcium phosphate.

[0026] In certain specific embodiments, the health food is a tablet, and the preparation method thereof comprises the following steps:

[0027] After the psyllium husk, oligoxylose and galactomannan are evenly mixed, microcrystalline cellulose, sodium starch glycolate and silicon dioxide are added and mixed for 20 to 30 minutes, and then magnesium stearate is added and mixed for 4 to 6 minutes. The material is discharged and tableted using a 19*8mm oval mold. The weight difference, disintegration time and hardness of the plain tablet are controlled during the tableting process. After tableting, brown film coating powder is added for tablet coating and product packaging, and the product is put into storage after passing the inspection.

[0028] The beneficial effect of the present invention is that the present invention provides a composition for improving constipation function, and the product is a composite combination of three components: psyllium husk, oligoxylose, and galactomannan, which has significant synergistic effect compared with similar compositions. The efficacy of the product is confirmed by human food trial experiments. The product is mild and stable in nature, does not cause obvious irritation to the gastrointestinal tract after use, and can be effectively used in the preparation of medicinal and edible products. The present invention also provides a preparation method of the composition to ensure that the powder does not clump and is evenly mixed. DETAILED DESCRIPTION

[0029] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments and comparative examples, the purpose of which is to understand the content of the present invention in detail, rather than to limit the present invention. All other technical solutions obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present invention.

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0031] Unless otherwise specified, the experimental reagents and instruments designed for the embodiments of the present invention and comparative examples are all commonly used ordinary reagents and instruments.

[0032] In the present invention, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are considered continuous and include the minimum and maximum values ​​of the range, as well as each value between the minimum and maximum values. Further, when multiple ranges are provided to describe features or characteristics, the ranges can be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.

[0033] Psyllium seed husk (English name: Psyllium seed husk) is the seed husk of the artificially cultivated Plantago ovata (Latin name: Plantago ovata). The dietary fiber content in Psyllium seed husk is as high as more than 80%. Usually, Psyllium seed husk is crushed to make Psyllium seed husk powder for use.

[0034] Xylooligosaccharides, also known as xylooligosaccharides, are functional polysaccharides formed by 2-7 xylose molecules linked by β-1,4 glycosidic bonds. Xylooligosaccharides are a natural active substance with good functionality and are widely found in plant tissues in nature. Xylooligosaccharides are usually produced by using wheat straw or corn straw as raw materials to extract xylan by steam explosion or high pressure cooking, and then further enzymatically hydrolyzed by xylanase.

[0035] Galactomannan is a polysaccharide containing a mannose backbone and a galactose side group. It is a polysaccharide with a linear (1-4)-linked β-D-mannose as the backbone and α-D-galactose (alpha-D-galactose) connected at their 6-linking points. Galactomannan is usually made from the endosperm pieces or gums of guar beans [Cyamops tetragonolobus (L.) Taub], sesbania beans, coumarin, cassia seeds, locust beans, etc., and is processed into a low-polymerization galactomannan by enzymatic hydrolysis with one or more enzymes such as galactosidase, hemicellulase, and protease, and purification.

[0036] The psyllium husk used in the examples of the present application was purchased from RCENTERPRISE; the xylo-oligosaccharide was purchased from Shandong Jianyihong Biopharmaceutical Co., Ltd.; and the galactomannan was purchased from Chengde Kangerrun Food Co., Ltd.

[0037] Example 1

[0038] An embodiment of the composition for improving constipation function of the present invention comprises the following components in parts by weight: 13 parts of psyllium husk, 5 parts of xylo-oligosaccharide and 19 parts of galactomannan, all of which are in powder form;

[0039] The galactomannan is hydrolyzed guar gum, and the galactomannan has a low molecular weight of 10-50 kDa;

[0040] Example 2

[0041] An embodiment of the composition for improving constipation function of the present invention is different from Example 1 only in that the product comprises the following components in parts by weight: 24 parts of psyllium husk, 6 parts of xylo-oligosaccharides and 12 parts of galactomannan, and all three components are in powder form.

[0042] The galactomannan is hydrolyzed guar gum, and the galactomannan has a low molecular weight of 10-50 kDa;

[0043] Example 3

[0044] An embodiment of the composition for improving constipation function of the present invention is different from Example 1 only in that the product comprises the following components in parts by weight: 15 parts of psyllium husk, 7 parts of xylo-oligosaccharides and 15 parts of galactomannan, and all three components are in powder form.

[0045] The galactomannan is hydrolyzed guar gum, and the galactomannan has a low molecular weight of 10-50 kDa;

[0046] Example 4

[0047] An embodiment of the composition for improving constipation function of the present invention is different from embodiment 1 only in that the galactomannan is hydrolyzed guar gum and the galactomannan has a high molecular weight of 150-180 kDa;

[0048] Comparative Example 1

[0049] A composition comprises the following components in parts by weight: 15 parts of psyllium husk and 7 parts of xylo-oligosaccharide, both in powder form.

[0050] The galactomannan is hydrolyzed guar gum, and has a low molecular weight of 10-50 kDa.

[0051] Comparative Example 2

[0052] A composition comprises the following components in parts by weight: 7 parts of xylo-oligosaccharide and 15 parts of galactomannan, both in powder form.

[0053] The galactomannan is hydrolyzed guar gum and has a low molecular weight of 10-50 kDa.

[0054] Comparative Example 3

[0055] A composition comprises the following components in parts by weight: 15 parts of psyllium husk and 15 parts of galactomannan, both in powder form.

[0056] The galactomannan is hydrolyzed guar gum and has a low molecular weight of 10-50 kDa.

[0057] Effect Test 1

[0058] In order to verify that the composition of the present invention has the effect of improving constipation, the physical properties of Examples 1-4 and Comparative Examples 1-3 were measured, as follows:

[0059] (1) Solubility test:

[0060] Take 10 g of each of Examples 1-4 and Comparative Examples 1-3, dissolve in 200 ml of water at a temperature of about 40° C., stir, and record the degree of solubility of each group of samples.

[0061] (2) Viscosity test:

[0062] Take 10g of each of Examples 1-4 and Comparative Examples 1-3, dissolve in 200ml of water at a temperature of about 40°C, stir, and measure the viscosity using a viscometer. If the viscosity exceeds the rotor range, dilute the proportion accordingly.

[0063] (3) Swelling degree test:

[0064] Take 10 g of each of Examples 1-4 and Comparative Examples 1-3, dissolve in 200 ml of water at a temperature of about 40° C., stir, and observe and record the changes of the materials in the beaker.

[0065] (4) Food tasting test:

[0066] Laboratory personnel consumed Examples 1-4 and Comparative Examples 1-3 within 3 weeks, and recorded the taste and gastrointestinal sensation after the consumption.

[0067] (5) In vitro simulation test:

[0068] Simulate gastrointestinal fluid conditions, measure changes in sample properties, and evaluate the feasibility of improving constipation.

[0069] Weigh the sample (about 10 g each) and place it in a 250 mL beaker, add 50 mL of 0.8 mg / mL pepsin solution (pepsin 1:3000, the dosage can be converted according to the enzyme activity), adjust the solution pH to 2, shake the shaker at a speed of 100 r / min (temperature about 37 ° C), digest for 3.5 hours, adjust the pH to 6.8 with 0.2 mol / L NaOH solution, add 10 mL of sodium dihydrogen phosphate-disodium hydrogen phosphate buffer, add 5 mL of 4.4 mg / mL trypsin solution (trypsin 1:250, the dosage can be converted according to the enzyme activity), adjust the solution pH to 6.8, shake the shaker at 100 r / min (temperature about 37 ° C), digest for 180 minutes, observe the changes in the sample, and measure the viscosity and swelling degree.

[0070] Table 1 Comparison of physicochemical information of the composition

[0071]

[0072] The treatment method in the "Chinese Expert Consensus on Chronic Constipation (2019, Guangzhou)" suggests that increasing dietary fiber can retain intestinal water and increase stool volume. "The Effect of Dietary Fiber on Functional Constipation Symptoms" shows that the role of dietary fiber is to promote stool expansion and increase stool viscosity. Therefore, laxative products need to have appropriate swelling capacity to facilitate the absorption of water in the intestine, increase stool volume, shorten defecation time, and improve defecation sensation. Galactomannan is a linear macromolecule, and the hydroxyl groups on the chain can interact with the two polysaccharides, psyllium husk and oligoxylose, to form a complex.

[0073] Through the experimental test of effect test one, it was found that the combined fermentability of psyllium husk, oligoxylose and galactomannan did not bring any adverse physical sensations, and was mild and non-irritating. The experimental results show that the viscosity of Example 4 using high molecular weight galactomannan is higher, and it is in a solid state after dissolution, with poor edible taste, large difficulty in swallowing, and not easy to dissolve. Comparative Examples 1, 2, and 3 have low viscosities, especially Comparative Example 2 has almost no consistency, and Comparative Examples 1-3 have weak improvements on fecal status, and do not improve defecation time relative to Examples 1-4. Example 1, Example 2 and Example 3 are more suitable gel states, all of which can improve defecation time and fecal status. The dissolution time of Example 2 is high, the consistency of Example 1 is low, and Example 3 has a higher taste evaluation, and still has a good physicochemical state after in vitro simulated gastrointestinal fluid.

[0074] Effect Test 2

[0075] Based on the results of the experiment of effect test 1, the composition of Example 3 was selected for process research. Taking powder production as an example, the effects of different process operations on the dispersion effect of the composition were explored.

[0076] Process Example 1: Add psyllium husk, xylo-oligosaccharide, galactomannan and auxiliary materials (maltodextrin, silicon dioxide) into a mixer and mix for 5 minutes.

[0077] Process Example 2: Add psyllium husk, xylo-oligosaccharide, galactomannan and auxiliary materials (maltodextrin, silicon dioxide) into a mixer and mix for 15 minutes.

[0078] Process Example 3: Add psyllium husk, xylo-oligosaccharide, galactomannan and auxiliary materials (maltodextrin, silicon dioxide) into a mixer and mix for 30 minutes.

[0079] Process Example 4: Add psyllium husk, xylo-oligosaccharide, galactomannan and auxiliary materials (resistant dextrin, silicon dioxide) into a mixer and mix for 15 minutes.

[0080] Process Example 5: Add psyllium husk, xylo-oligosaccharide, galactomannan and auxiliary materials (corn starch, silicon dioxide) into a mixer and mix for 15 minutes.

[0081] Process Example 6: Add psyllium husk, xylo-oligosaccharide, galactomannan and auxiliary materials (maltodextrin, tricalcium phosphate) into a mixer and mix for 15 minutes.

[0082] Process Example 7: Premix the psyllium husk with auxiliary materials (maltodextrin, silicon dioxide), and then add it into a mixer together with oligoxylan and galactomannan, and mix for 5 minutes.

[0083] Process Example 8: Premix xylo-oligosaccharide with auxiliary materials (maltodextrin, silicon dioxide), and then add them into a mixer together with psyllium husk and galactomannan, and mix for 5 minutes.

[0084] Process Example 9: Premix galactomannan with auxiliary materials (maltodextrin, silicon dioxide), and then add them into a mixer together with psyllium husk and xylo-oligosaccharide, and mix for 5 minutes.

[0085] Table 2 Dispersion effect of the composition under different processes

[0086]

[0087]

[0088] The powders of the three materials, psyllium husk, oligoxylose and galactomannan, have electrostatic interactions, and when mixed, there is false clumping due to static electricity. It can be found from process examples 1-3 that increasing the mixing time can improve the clumping problem and improve the mixing uniformity. Process examples 2 and 4-6 are all mixed for 15 minutes, and different auxiliary material systems are used to obtain good mixing effects. In process examples 7-9, the three raw materials are pre-mixed separately, and the total mixing time of the three process examples is 5 minutes, which improves the clumping and dispersion of the components. Through process research, several suitable auxiliary material systems are obtained, and suitable mixing time and mixing methods are explored. Subsequent products can comprehensively consider factors such as operational convenience, mixing time, and production efficiency, and can be further optimized during specific production.

[0089] Effect Test 3

[0090] Based on the results of the effects test 1 and the effects test 2, human food testing experiments were conducted on the products obtained in Example 3 and the blank control group, as follows:

[0091] (1) Research subjects

[0092] Inclusion criteria: (1) those with decreased bowel movement frequency and increased stool hardness; (2) those with bowel movement ≤ 3 times a week; (3) those without organic constipation; (4) those with habitual constipation; (5) those aged 18-75 years

[0093] Exclusion criteria: (1) Those who cannot take food orally or cannot take the test sample as prescribed; (2) Those with unclear complaints; (3) Those who are too weak to undergo the test; (4) Those who have undergone surgical operations within 30 days and have constipation symptoms; (5) Those who have recent difficulty in defecation due to serious organic lesions (colon cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease, etc.); (6) Those with severe constipation accompanied by pain; (7) Those who have had acute gastrointestinal diseases within 30 days; (8) Pregnant and menstruating women; (9) Patients with serious systemic diseases such as cardiovascular, liver, kidney and hematopoietic system diseases; (10) Those who are being treated for other concomitant diseases; (11) Those who take items related to the test function in the short term, which may affect the judgment of the results.

[0094] There are 100 subjects who meet the above conditions.

[0095] (2) Experimental plan

[0096] The above research subjects were randomly divided into Example 3 group and a blank control group (basically divided equally, with 1 to 2 people allowed to change). The frequency of administration was once a day, 10g each time, taken on an empty stomach. When taking, add about 200ml of warm water to the above test sample, mix and drink it. The defecation-related conditions of all subjects were tested during the introduction period of 1 week before the trial (T0), the first week of the trial (T1), the second week of the trial (T2), and the observation period of 1 week after the trial (T3). In addition, during the trial, record whether any adverse reactions occurred.

[0097] The test results are shown in Tables 3 to 7.

[0098] Among the subjects, 39 were male, accounting for 39%; and 61 were female, accounting for 61%. Among the subjects, 1% were aged 18-29, 8% were aged 30-39, 10% were aged 40-49, 34% were aged 50-59, 27% were aged 60-69, and 20% were aged 70-75. Among the subjects, 26% had a body mass index (BMI) between 18.5 and 22.9, 69% had a body mass index (BMI) between 23.0 and 27.9, and 5% had a body mass index ≥ 28.0. There were no significant differences in age (P = 0.189), gender (P = 0.543), and BMI (P = 0.158) (P>0.05). The baseline status of the subjects was balanced, which was suitable for human food testing.

[0099] Table 3 Subjects' physical examination information

[0100]

[0101]

[0102]

[0103] Table 4 Defecation frequency of subjects (mean ± SD)

[0104]

[0105] Note: T0 is the introduction period, T1 is the first week of intervention, T2 is the second week of intervention, and T3 is the observation period.

[0106] Different letters in the same row indicate statistically significant differences within the groups (P<0.05)

[0107] *Indicates that the difference between the two groups at the same time was statistically significant (P<0.05)

[0108] As shown in Table 4, the specific weekly bowel movement number (mean ± standard deviation) of the subject during the four-week study period, the difference in the number of bowel movements in the embodiment 3 group during the four-week study period has a significant difference (P < 0.001), indicating that the number of bowel movements in the embodiment 3 group during the four-week study period has changed, especially in the intervention of the second cycle bowel movement number mean value reached 5.08 times, compared with 2.35 times in the introduction period, there is a significant improvement, and the number of bowel movements in a week is maintained in the observation period. Mean> 3 times, indicating that the effect of the test sample is maintained. The difference in the number of bowel movements of the blank control group subjects during the four-week study period is not statistically significant (P > 0.05). The two groups are compared, wherein the difference in the introduction period is not statistically significant (P > 0.05), and the difference in the intervention of the first week, the second week and the observation period has a significant difference (P < 0.05), especially the difference in the second week of the intervention increases, indicating that the test sample has a significant effect after two weeks of trial feeding, and the effect is maintained after one week of trial feeding.

[0109] Table 5 Defecation difficulty of the subjects (mean ± standard deviation)

[0110]

[0111] Note: T0 is the introduction period, T1 is the first week of intervention, T2 is the second week of intervention, and T3 is the observation period.

[0112] Different letters in the same row indicate statistically significant differences within the groups (P<0.05)

[0113] *Indicates that the difference between the two groups at the same time was statistically significant (P<0.05)

[0114] As shown in Table 5, the specific degree of difficulty in defecation of the subjects during the four-week study (grade mean ± standard deviation) shows that the difference in the degree of difficulty in defecation of the embodiment 3 group during the four-week study has a significant difference (P<0.001), indicating that the degree of difficulty in defecation of the embodiment 3 group during the four-week study has changed, especially in the intervention of the second cycle, the mean value of the degree of difficulty in defecation has been reduced to 0.54, and it has been reduced to 0.52 here during the observation period, which is significantly improved compared to 1.42 in the introduction period. The number of bowel movements of the blank control group subjects during the four-week study period did not differ statistically (P>0.05). Compared with the two groups, the difference in the introduction period was not statistically significant (P>0.05), while the difference between the intervention period and the observation period was significantly different (P<0.05), indicating that the test sample has a significant effect after the trial, and the effect is maintained for one week after the trial is stopped.

[0115] Table 6 Defecation duration of the subjects (mean ± SD)

[0116]

[0117] Note: T0 is the introduction period, T1 is the first week of intervention, T2 is the second week of intervention, and T3 is the observation period.

[0118] Different letters in the same row indicate statistically significant differences within the groups (P<0.05)

[0119] *Indicates that the difference between the two groups at the same time was statistically significant (P<0.05)

[0120] As shown in Table 6, the specific defecation duration (mean ± standard deviation) of the subjects during the four-week study period, the difference in the number of defecations in the three groups of embodiments during the four-week study period was significantly different (P<0.001), indicating that the number of defecations in the three groups of embodiments changed during the four-week study period, especially in the intervention of the second cycle, the average defecation duration was reduced to 9.40 minutes, which was significantly improved compared to 15.30 minutes in the introduction period, and the defecation duration was kept close to the intervention of the second week in the observation period for one week, indicating that the effect of the test sample was maintained. The number of defecations of the subjects in the blank control group was not statistically significant during the four-week study period (P>0.05). Compared with the two groups, the difference between the introduction period and the first week of intervention was not statistically significant (P>0.05), while the difference between the second week of intervention and the observation period was significantly different (P<0.05), indicating that the test sample was significantly effective after two weeks of trial feeding, and the effect was maintained for one week after the trial feeding was stopped.

[0121] There were no obvious adverse reactions during the tasting process. After the tasting experiment, the subjects received the product and expressed a certain interest and willingness to eat the product. The composition for improving constipation disclosed in the present invention has been verified by experiments to have an effect of improving constipation and a good eating experience.

[0122] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A composition, characterized in that Contains the following ingredients: psyllium husk, xylo-oligosaccharide, galactomannan.

2. The composition according to claim 1, characterized in that The galactomannan is hydrolyzed guar gum.

3. The composition according to claim 2, characterized in that The molecular weight of the galactomannan is 1-50 kDa.

4. The composition according to claim 1, characterized in that Among the components of the composition, the mass ratio of psyllium husk, xylo-oligosaccharide and galactomannan is (10-25): (4-8): (10-20).

5. The composition according to claim 4, characterized in that Among the components of the composition, the mass ratio of psyllium husk, xylo-oligosaccharide and galactomannan is 15:7:

15.

6. Use of the composition according to any one of claims 1 to 5 in the preparation of a product for improving constipation function.

7. The use according to claim 6, characterized in that The products include common food and health food.

8. The use according to claim 7, characterized in that The health food also includes supplementary materials acceptable to health foods.

9. The use according to claim 7, characterized in that The dosage forms of the health food include tablets, powders and capsules.

10. A method for preparing a health food for improving constipation, characterized in that: Transfer the psyllium husk, xylooligosaccharide, galactomannan and auxiliary materials to a mixing device and mix for 25 to 35 minutes, discharge the materials, and seal and package them; wherein the mass ratio of psyllium husk, xylooligosaccharide and galactomannan is (10 to 25): (4 to 8): (10 to 20); Preferably, any one of psyllium husk, xylo-oligosaccharide and galactomannan is pre-mixed with auxiliary materials, and then the mixture is transferred to a mixing device together with the remaining two components and mixed for 5 minutes, discharged, and sealed and packaged.

Images